April 16, 2025 Nvidia’s $5.5B AI Chip Crunch and ASML’s Tariff Jitters
Apple: Dividend Growth Ahead, But a Near-Term Slide Likely
April 23, 2025 Oleksandr Orlovskyi: Reviews, Biography, and All About Cryptocurrency
March 12, 2025 Features of exchanging USDC ERC20 to Bank Transfer
February 19, 2025 Why Stock Caps Matter When Building a Diversified Portfolio
February 5, 2025 Top 5 Coins for the Maximum Passive Income from Staking by 2024
January 21, 2025 Trading Stocks With AI: A Modern Approach
Medtronic (MDT) Stock Forecast for 2025, 2026, 2027. Sell or Buy?
Updated: April 29, 2025 (20:27)
Sector: HealthcareThe share price of Medtronic plc. (MDT) now
Analysts predictions
Full report
This Week
|
Bullish | Opinions: 2 (1/1/0) |
Previous Week
|
Neutral | Opinions: Na |
Two Weeks Ago
|
Neutral | Opinions: Na |
Three Weeks Ago
|
Neutral | Opinions: 1 |
Are you interested in Medtronic plc. stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Medtronic stock price in 2025, 2026, 2027. How much will one Medtronic share be worth in 2025 - 2027?
When should I take profit in Medtronic stock? When should I record a loss on Medtronic stock? What are analysts' forecasts for Medtronic stock? What is the future of Medtronic stock? We forecast Medtronic stock performance using neural networks based on historical data on Medtronic stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.
Medtronic stock prediction results are shown below and presented in the form of graphs, tables and text information, divided into time intervals. (Next month, 2025, 2026, 2027, and ) The final quotes of the instrument at the close of the previous trading day are a signal to adjust the forecasts for Medtronic shares. This happens once a day.
Historical and forecast chart of Medtronic stock
The chart below shows the historical price of Medtronic stock and a prediction chart for the next month.
For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast,
and Weighted Average Best Forecast. Detailed values for the Medtronic stock price can be found in the table below.
Long-term forecasts by years.
Medtronic plc. Analysts predictions review

Medtronic's stock faces a mixed outlook, primarily shaped by supply chain challenges, cost inflation, and competitive pressures affecting near-term performance. While operational risks remain, the company benefits from its strong cash generation, consistent dividend payouts, and attractive valuation levels. Long-term growth potential is supported by innovation, emerging market expansion, and a diversified product portfolio. However, stagnating revenue growth and geopolitical pressures, particularly in key markets like China, may limit upside potential in the short term. Overall, while dividend yield supports income-focused investors, a lack of clear growth catalysts keeps broader market enthusiasm subdued.

Medtronic: Assessing Value Amid Dividend Stability and Market Challenges

The company demonstrates a robust positioning as a dividend aristocrat, highlighting its longstanding ability to deliver reliable dividend payouts. This track record underscores Medtronic's steady cash generation and disciplined capital allocation, which will likely appeal to income-focused investors despite near-term macroeconomic headwinds.
Medtronic's valuation metrics suggest it may be trading at an attractive discount relative to its historical averages and peers. The potential for multiple expansion as market conditions normalize strengthens the case for long-term capital appreciation. However, the weight of external factors, such as industry-wide pricing pressures, demands caution when evaluating immediate upside potential.
Key Factors Influencing Performance
Operational performance remains a crucial point of assessment, as ongoing supply chain challenges and cost inflation have factored into profitability metrics. While management's efforts toward operational efficiency offer optimism, execution risks remain significant in the short term.
The competitive landscape in the medical device industry continues to intensify, posing both opportunities and challenges for Medtronic. Product innovation and R&D investments are critical to maintaining market leadership, but underperformance in this area could weigh on future growth prospects.

Medtronic: A Prime Opportunity for Value Investors

Medtronic's long-term growth potential is underpinned by its robust portfolio of medical devices, which addresses a broad range of critical healthcare needs. The company's strategic focus on innovation and its diversified product lineup contribute strongly to its resilience, even in times of economic uncertainty, as noted by the author.
Key Drivers Impacting Medtronic's Future
Recent challenges, such as supply chain pressures and regulatory hurdles, are highlighted as near-term headwinds for the company. While these factors might slightly dampen profit margins in the immediate quarters, their long-term impact is likely muted due to Medtronic's operational scale and ability to adapt.
The valuation of MDT stock remains compelling, with the author emphasizing its current pricing as an attractive entry point for investors. This is reinforced by the company's robust dividend yield and historical commitment to shareholder returns, which enhance its appeal during market pullbacks.
Lastly, Medtronic's commitment to emerging market growth could serve as a significant catalyst for revenue expansion. Its strategic positioning in high-growth regions aligns with global healthcare demand trends, offering a substantial upside for long-term investors.

Medtronic: Solid Fundamentals, But Growth Challenges Persist

Medtronic (MDT) demonstrates strong stability stemming from its established medical device business, which generates consistent cash flows and enjoys robust market share. However, according to the author, the company's innovation pipeline appears underwhelming, limiting its ability to significantly accelerate high-margin growth opportunities.
Recent geopolitical and regulatory pressures have complicated Medtronic's international operations, particularly in key growth markets like China. As emphasized by the author, these challenges could constrain revenue expansion in the near term.
Challenges with Growth Trajectory and Valuation
Revenue growth for Medtronic has been relatively stagnant, with tempered guidance that highlights the struggle to deliver substantial performance improvements. Additionally, concerns related to Medtronic's current valuation levels suggest that the stock may remain range-bound absent a major catalyst or acceleration in top-line results.
On the positive side, the company's dividend yield remains a compelling feature for income-focused investors. The author's view supports this, though dividend-focused strategies may not offset declining enthusiasm from growth and value investors.
Medtronic continues to face headwinds with sluggish growth metrics, marked by persistently single-digit earnings increases. This growth rate raises concerns about the company’s ability to maintain competitive positioning within a rapidly evolving medtech landscape.
Challenges Impacting Medtronic’s Near-Term Performance
A key factor influencing Medtronic's sluggish performance appears to be margin pressures stemming from inflationary costs and supply chain constraints. These issues are likely to undermine profitability and cast doubt on the firm’s ability to achieve operational leverage in a high-cost environment.
Additionally, the company’s product portfolio diversification, while extensive, has yet to translate into significant revenue acceleration. This indicates a potential misalignment between product offerings and market demand, which could hinder the firm’s ability to capture growth opportunities.
Medtronic’s dividend yield remains a redeeming factor, offering stability for income-focused investors. However, inadequate earnings growth could limit the company’s capacity to sustain or increase dividend payouts over time.
Lastly, the broader macroeconomic environment, including rising interest rates and potential recessionary risks, poses additional challenges. These factors could weigh on Medtronic’s valuation multiples, pressuring the stock further in the short term.
The company's recent advancements in medical technology and innovation across its product portfolio suggest a strong pipeline that could reinvigorate revenue growth. By focusing on high-growth areas such as robotics and minimally invasive therapies, Medtronic is positioning itself to capture market share and offset pressures from competitive dynamics.
Focus on Margin Improvement and Cost Controls
Medtronic's ability to enhance operational efficiencies and address supply chain disruptions will be critical in sustaining profitability. The management's emphasis on cost optimization measures reflects a robust strategy to preserve margins amid macroeconomic headwinds.
The upcoming earnings release could be pivotal in signaling demand recovery and procedural volumes across its key therapeutic segments. A robust rebound in elective procedures and increased adoption of Medtronic's flagship offerings could provide a solid upside to near-term revenue projections.
Risks related to foreign exchange volatility and regulatory uncertainties remain a potential overhang for the stock. Mitigating these factors will require thoughtful hedging strategies and proactive regulatory compliance to maintain investor confidence.
Medtronic (MDT) currently faces a valuation disconnect, with the stock trading below its historical multiples despite steady revenue growth. This undervaluation is attributed to persistent concerns surrounding operational inefficiencies and execution risks, especially in competitive markets.
Investment in innovation has been a cornerstone of MDT’s strategy, yet the commercial viability of its pipeline remains under scrutiny. The author emphasizes that while innovation is critical for long-term growth, it has not translated effectively into immediate shareholder value or meaningful market share gains in key segments.
Key Factors Influencing MDT's Prospects
Macroeconomic headwinds, including inflationary pressures and global supply chain disruptions, have exacerbated margin erosion for MDT. These external challenges limit the company's ability to scale profitability in the near term, keeping downward pressure on the stock price.
Leadership and operational restructuring appear promising but require time to deliver measurable results. The article cautions that despite a strategic pivot, the lagging impact on the balance sheet may deter investor confidence in the interim.
Medtronic's current valuation reflects a discounted entry point, offering a compelling opportunity for income-oriented investors to capitalize on the company’s long-standing dividend growth history and status as a Dividend Aristocrat. The author emphasizes that the combination of financial stability, consistent cash flow generation, and shareholder returns positions the stock as an attractive holding during market uncertainty.
Growth Drivers and Market Position
A key factor identified is Medtronic’s robust portfolio diversification across healthcare technologies, which supports organic growth potential while reducing risks associated with market cyclicality. This diversity allows the company to capture incremental market share in both developed and emerging markets, creating long-term revenue stability that underpins shareholder confidence.
Another critical point concerns the ongoing operational efficiencies driven by management, which are expected to bolster profit margins and offset cost pressures from macroeconomic headwinds. Improved profitability metrics could act as a catalyst to boost investor sentiment and, ultimately, the share price over time.
The stock’s sensitivity to broader market trends and healthcare-specific reimbursement policies is noted, requiring investors to monitor regulatory and macroeconomic developments closely. However, the underlying argument suggests that these headwinds are largely priced into Medtronic's current valuation, presenting limited downside risk and improving upside potential.
Medtronic's status as a Dividend Aristocrat underscores its consistent financial stability, providing investors confidence in reliable income generation. The author's argument about the company's strong history of dividend growth highlights its appeal to income-focused investors, particularly given its track record across economic cycles.
The company's innovation pipeline, particularly in medical technologies, is a key catalyst for future growth. As highlighted, breakthroughs in surgical robotics and diabetes devices have the potential to significantly expand Medtronic's addressable market, enhancing its competitive positioning.
Financial Resilience and Strategic Growth Drivers
Concerns surrounding near-term headwinds, such as currency fluctuations and supply chain pressures, may pose temporary challenges. However, the author notes that Medtronic's robust cash flow and diversified portfolio position it strongly to weather such issues with minimal impact on long-term performance.
The stock's current valuation appears attractive, particularly when considering the company's industry leadership and ongoing investments in R&D. The author's emphasis on the gap between price and intrinsic value suggests a potential opportunity for capital appreciation as the broader market recognizes Medtronic's growth potential.
Medtronic's financial resilience stands out as a pivotal factor in sustaining investor confidence. The company's strong cash flow generation and robust balance sheet provide it the flexibility to invest in innovation and growth initiatives while also maintaining shareholder returns through dividends and buybacks.
Product pipeline innovation is a key driver of Medtronic's long-term growth potential. The author highlights the recent advancements across its core therapeutic areas, particularly in cardiovascular and diabetes management, which could act as catalysts for revenue growth in the face of escalating competition.
Geographical Expansion and Market Diversification
Medtronic's strategic focus on expanding its presence in emerging markets is an important growth lever. The company's ability to cater to growing healthcare demand globally, complemented by its adaptive pricing strategy, positions it to capture significant market share in price-sensitive regions.
Operational efficiency and cost optimization programs are also contributing positively to Medtronic’s margins. The company demonstrates a commitment to mitigating external pressures, such as inflationary costs, which should help maintain profitability and safeguard its long-term valuation.
Medtronic's recent upward revision in guidance underscores its management's confidence in operational improvements and future revenue growth, driven by a strong product pipeline and successful execution in key markets. This strategic positioning is expected to lend near-term support to the stock price, particularly as it reflects a commitment to delivering steady earnings growth.
The company's reliable and competitive dividend yield offers a compelling incentive for income-focused investors, especially in a volatile macroeconomic environment. As dividends are a critical component of total shareholder returns, Medtronic's consistent payout policy enhances its attractiveness as a long-term value play.
Growth Prospects Blended with Valuation
The stock's current valuation appears discounted relative to its historical averages and industry peers, creating a strong margin of safety for investors. This combination of undervaluation and improving fundamentals positions the stock as an attractive entry point at present levels.
However, external risks such as potential regulatory pressures and macroeconomic uncertainty could pose challenges, albeit their impact appears limited given the company's diverse geographic and product exposure. These factors warrant monitoring but are unlikely to derail Medtronic's positive trajectory.
Medtronic is a large medical device company headquartered in Dublin, Ireland. It is one of the largest medical device companies. Works in over 140 countries. Medtronic has six main divisions, each of which develops and manufactures devices and treatments for a variety of chronic conditions including heart failure, Parkinson’s disease, urinary incontinence, Down’s syndrome, obesity, chronic pain, diabetes and others, for a total of more than 30 different diseases.
In 2017, the company earned more than $ 29 billion, which is 9 billion more than in 2015, the net income for the 2017 financial year of the company increased by $ 1 billion compared to 2015 and amounted to more than $ 5 billion.
Medtronic was founded in 1949 as a medical device repair company in a garage in northeastern Minneapolis by Earl Bakken and Palmer Hermundsl. While working for the company, Earl Bakken met Dr. Walton Lillehei, one of the first cardiac surgeons. Lillehei was disappointed with the pacemakers of the time that had to be plugged in, especially after the 1957 power outage on Halloween. Lillehei then proposed to Bakken the idea of a battery-operated pacemaker.
Medtronic daily forecast for a month
Date | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
May 01 | 84.43 | 83.71 | 85.04 | 1.59 |
May 02 | 84.28 | 83.29 | 85.38 | 2.51 |
May 03 | 83.69 | 82.97 | 84.18 | 1.45 |
May 04 | 83.24 | 82.77 | 83.82 | 1.27 |
May 05 | 82.62 | 82.16 | 83.25 | 1.33 |
May 06 | 83.73 | 83.18 | 84.65 | 1.77 |
May 07 | 84.13 | 83.39 | 85.14 | 2.10 |
May 08 | 84.03 | 83.49 | 85.26 | 2.11 |
May 09 | 83.73 | 82.69 | 84.28 | 1.92 |
May 10 | 83.19 | 82.35 | 84.13 | 2.16 |
May 11 | 83.56 | 83.21 | 84.31 | 1.33 |
May 12 | 84.43 | 83.74 | 85.63 | 2.26 |
May 13 | 83.87 | 82.68 | 85.13 | 2.96 |
May 14 | 83.96 | 83.22 | 85.05 | 2.20 |
May 15 | 85.42 | 85.07 | 86.12 | 1.22 |
May 16 | 86.99 | 85.82 | 88.21 | 2.78 |
May 17 | 87.67 | 87.07 | 88.74 | 1.91 |
May 18 | 87.86 | 86.72 | 88.74 | 2.33 |
May 19 | 86.30 | 85.57 | 87.62 | 2.40 |
May 20 | 84.69 | 83.50 | 85.99 | 2.98 |
May 21 | 85.22 | 83.97 | 85.86 | 2.25 |
May 22 | 85.76 | 84.61 | 86.76 | 2.53 |
May 23 | 86.28 | 85.10 | 86.72 | 1.91 |
May 24 | 87.64 | 86.83 | 88.97 | 2.46 |
May 25 | 88.04 | 87.44 | 88.80 | 1.55 |
May 26 | 87.72 | 87.04 | 88.46 | 1.63 |
May 27 | 87.01 | 85.77 | 87.88 | 2.45 |
May 28 | 87.65 | 87.26 | 88.40 | 1.31 |
May 29 | 88.18 | 87.52 | 88.69 | 1.33 |
May 30 | 88.23 | 86.85 | 88.83 | 2.28 |
Medtronic Daily Price Targets
Medtronic Stock Forecast 05-01-2025.
Forecast target price for 05-01-2025: $84.43.
Positive dynamics for Medtronic shares will prevail with possible volatility of 1.569%.
Pessimistic target level: 83.71
Optimistic target level: 85.04
Medtronic Stock Forecast 05-02-2025.
Forecast target price for 05-02-2025: $84.28.
Negative dynamics for Medtronic shares will prevail with possible volatility of 2.448%.
Pessimistic target level: 83.29
Optimistic target level: 85.38
Medtronic Stock Forecast 05-03-2025.
Forecast target price for 05-03-2025: $83.69.
Negative dynamics for Medtronic shares will prevail with possible volatility of 1.432%.
Pessimistic target level: 82.97
Optimistic target level: 84.18
Medtronic Stock Forecast 05-04-2025.
Forecast target price for 05-04-2025: $83.24.
Negative dynamics for Medtronic shares will prevail with possible volatility of 1.251%.
Pessimistic target level: 82.77
Optimistic target level: 83.82
Medtronic Stock Forecast 05-05-2025.
Forecast target price for 05-05-2025: $82.62.
Negative dynamics for Medtronic shares will prevail with possible volatility of 1.310%.
Pessimistic target level: 82.16
Optimistic target level: 83.25
Medtronic Stock Forecast 05-06-2025.
Forecast target price for 05-06-2025: $83.73.
Positive dynamics for Medtronic shares will prevail with possible volatility of 1.741%.
Pessimistic target level: 83.18
Optimistic target level: 84.65
MDT (MDT) Monthly Stock Prediction for 2025
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
May. | 91.99 | 89.04 | 98.24 | 9.36 |
Jun. | 96.49 | 89.55 | 101.61 | 11.87 |
Jul. | 96.40 | 89.65 | 102.09 | 12.18 |
Aug. | 99.77 | 95.78 | 104.96 | 8.75 |
Sep. | 101.37 | 97.92 | 107.35 | 8.78 |
Oct. | 111.20 | 107.31 | 115.20 | 6.85 |
Nov. | 111.20 | 103.97 | 116.98 | 11.12 |
Dec. | 115.43 | 110.81 | 117.85 | 5.97 |
Medtronic forecast for this year
Medtronic Stock Prediction for May 2025
An uptrend is forecast for this month with an optimal target price of $91.9869. Pessimistic: $89.04. Optimistic: $98.24
Medtronic Stock Prediction for Jun 2025
An uptrend is forecast for this month with an optimal target price of $96.4942. Pessimistic: $89.55. Optimistic: $101.61
Medtronic Stock Prediction for Jul 2025
An downtrend is forecast for this month with an optimal target price of $96.3977. Pessimistic: $89.65. Optimistic: $102.09
Medtronic Stock Prediction for Aug 2025
An uptrend is forecast for this month with an optimal target price of $99.7717. Pessimistic: $95.78. Optimistic: $104.96
Medtronic Stock Prediction for Sep 2025
An uptrend is forecast for this month with an optimal target price of $101.368. Pessimistic: $97.92. Optimistic: $107.35
Medtronic Stock Prediction for Oct 2025
An uptrend is forecast for this month with an optimal target price of $111.201. Pessimistic: $107.31. Optimistic: $115.20
Medtronic Stock Prediction for Nov 2025
An downtrend is forecast for this month with an optimal target price of $111.201. Pessimistic: $103.97. Optimistic: $116.98
Medtronic Stock Prediction for Dec 2025
An uptrend is forecast for this month with an optimal target price of $115.426. Pessimistic: $110.81. Optimistic: $117.85
Medtronic (MDT) Monthly Stock Prediction for 2026
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jan | 115.20 | 107.36 | 121.99 | 11.99 |
Feb | 116.23 | 107.28 | 123.90 | 13.42 |
Mar | 108.91 | 100.85 | 117.41 | 14.10 |
Apr | 103.68 | 99.33 | 107.62 | 7.71 |
May | 104.20 | 97.22 | 111.91 | 13.13 |
Jun | 111.60 | 107.25 | 118.63 | 9.60 |
Jul | 118.96 | 113.61 | 122.53 | 7.28 |
Aug | 114.09 | 109.75 | 120.59 | 8.99 |
Sep | 113.40 | 107.17 | 115.67 | 7.35 |
Oct | 119.53 | 116.78 | 124.67 | 6.33 |
Nov | 121.68 | 119.24 | 131.41 | 9.26 |
Dec | 111.09 | 106.65 | 115.31 | 7.51 |
Medtronic (MDT) Monthly Stock Prediction for 2027
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jan | 110.20 | 106.68 | 116.93 | 8.77 |
Feb | 109.10 | 106.05 | 112.92 | 6.09 |
Mar | 113.03 | 107.72 | 121.39 | 11.27 |
Apr | 120.04 | 112.11 | 123.04 | 8.88 |
May | 116.80 | 108.97 | 119.48 | 8.80 |
Jun | 111.07 | 103.19 | 113.63 | 9.19 |
Jul | 121.96 | 117.32 | 124.76 | 5.96 |
Aug | 111.71 | 107.13 | 114.62 | 6.53 |
Sep | 105.01 | 97.45 | 113.31 | 13.99 |
Oct | 97.03 | 93.05 | 99.65 | 6.62 |
Nov | 93.05 | 88.58 | 97.80 | 9.42 |
Dec | 98.82 | 96.35 | 106.03 | 9.13 |
Medtronic information and performance
20 ON HATCH, LOWER HATCH STREET, DUBLIN, IE
Market capitalization of the Medtronic plc. is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of MDT shares in the company outstanding by the market price of one share.
EBITDA of Medtronic is earnings before interest, income tax and depreciation of assets.
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward P/E uses projections of future earnings instead of final numbers.
Enterprise Value (EV) /Revenue
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Number of issued ordinary shares
Number of freely tradable shares
Shares Short Prior Month - the number of shares in short positions in the last month.
Medtronic (MDT) stock dividend
Medtronic last paid dividends on 03/28/2025. The next scheduled payment will be on 04/11/2025. The amount of dividends is $2.79 per share. If the date of the next dividend payment has not been updated, it means that the issuer has not yet announced the exact payment. As soon as information becomes available, we will immediately update the data. Bookmark our portal to stay updated.
Last Split Date: 01/01/1970
Splitting of shares is an increase in the number of securities of the issuing company circulating on the market due to a decrease in their value at constant capitalization.
For example, a 5: 1 ratio means that the value of one share will decrease 5 times, the total amount will increase 5 times. It is important to understand that this procedure does not change the capitalization of the company, as well as the total value of assets held in private hands.
FAQ (Frequently Asked Questions about Medtronic Stock)
Should I Buy Medtronic Shares in 2025 year?
Does Medtronic pay dividends?
Which economic sector do Medtronic's shares belong to?
Which other securities belong to the same sector as Medtronic's shares?
Related stocks from Healthcare sector
All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.